Top

Published in:

01-06-2018 | Clinical Study

Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation

Authors: Fu Zhao, Bo Wang, Zhijun Yang, Qiangyi Zhou, Peng Li, Xingchao Wang, Jing Zhang, Junting Zhang, Pinan Liu

Published in: Journal of Neuro-Oncology | Issue 2/2018

Abstract

Surgical treatment of vestibular schwannoma (VS) in patients with neurofibromatosis type 2 (NF2) along with functional preservation of cranial nerves is challenging. The aim of this study was to analyze the outcomes of hearing and facial nerve function in patients with NF2 who underwent large-size VS (> 2 cm) surgery. From 2006 to 2016, one hundred and forty NF2 patients were included with 149 large-size VS resections using retrosigmoid approach. Hearing function was classified according to the American Academy of Otolaryngology–Head and Neck Surgery (AAO–HNS) criteria. Preoperative and one-year postoperative facial nerve function were both assessed using the House–Brackmann (H–B) grading scale. A multivariate logistic regression was performed to identify preoperative predictors for facial function outcomes. No operative death we noted. Total tumor removal was achieved in 82.6% of the operated VSs. The anatomical integrity of the facial nerve was preserved in 67.8% of surgeries. Good facial nerve function (H–B Grades I–III) was maintained in 49.6% of patients at 12 months after surgery. Tumor size larger than 3 cm and preoperative facial weakness related with worse outcome of facial nerve function (P < 0.001; for both). Hearing preservation surgeries were attempted in 31 ears. Class B or C hearing according to the AAO–HNS criteria was maintained in 7 ears (22.5%), and measurable hearing was maintained 11 ears (35.5%). It is challenging to maintain hearing and facial nerve function in NF2 patients with large VSs. Early surgical intervention is an appropriate choice to decrease the risk of neurological functions deficit.

Asthagiri AR, Parry DM, Butman JA et al (2009) Neurofibromatosis type 2. Lancet 373:1974–1986. https://doi.org/10.1016/S0140-6736(09)60259-2 CrossRefPubMedPubMedCentral

Baser ME, Friedman JM, Joe H et al (2011) Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genet Med 13:576–581. https://doi.org/10.1097/GIM.0b013e318211faa9 CrossRefPubMed

Baser ME, Kuramoto L, Joe H et al (2004) Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet 75:231–239. https://doi.org/10.1086/422700 CrossRefPubMedPubMedCentral

Baser ME, Makariou EV, Parry DM (2002) Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2. J Neurosurg 96:217–222. https://doi.org/10.3171/jns.2002.96.2.0217 CrossRefPubMed

Blakeley JO, Plotkin SR (2016) Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol 18:624–638. https://doi.org/10.1093/neuonc/nov200 CrossRefPubMedPubMedCentral

Brackmann DE, Fayad JN, Slattery WH 3rd, et al. (2001) Early proactive management of vestibular schwannomas in neurofibromatosis type 2. Neurosurgery 49:274–280 (discussion 280–273)PubMed

Dewan R, Pemov A, Kim HJ et al (2015) Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas. Neuro Oncol 17:566–573. https://doi.org/10.1093/neuonc/nou317 CrossRefPubMed

Dirks MS, Butman JA, Kim HJ et al (2012) Long-term natural history of neurofibromatosis type 2-associated intracranial tumors. J Neurosurg 117:109–117. https://doi.org/10.3171/2012.3.JNS111649 CrossRefPubMedPubMedCentral

Evans DG, Baser ME, O’Reilly B et al (2005) Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 19:5–12. https://doi.org/10.1080/02688690500081206 CrossRefPubMed

10.

Evans DG, Howard E, Giblin C et al (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327–332. https://doi.org/10.1002/ajmg.a.33139 CrossRefPubMed

11.

Jaaskelainen J, Paetau A, Pyykko I et al (1994) Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases. J Neurosurg 80:541–547. https://doi.org/10.3171/jns.1994.80.3.0541 CrossRefPubMed

12.

Jung S, Kang SS, Kim TS et al (2000) Current surgical results of retrosigmoid approach in extralarge vestibular schwannomas. Surg Neurol 53:370–377 (discussion 377–378)CrossRefPubMed

13.

Kanzaki J, Tos M, Sanna M et al (2003) New and modified reporting systems from the consensus meeting on systems for reporting results in vestibular schwannoma. Otol Neurotol 24:642–648 (discussion 648–649)CrossRefPubMed

14.

MacNally SP, Rutherford SA, King AT et al (2009) Outcome from surgery for vestibular schwannomas in children. Br J Neurosurg 23:226–231. https://doi.org/10.1080/02688690902968844 CrossRefPubMed

15.

Mallory GW, Pollock BE, Foote RL et al (2014) Stereotactic radiosurgery for neurofibromatosis 2-associated vestibular schwannomas: toward dose optimization for tumor control and functional outcomes. Neurosurgery 74:292–300. https://doi.org/10.1227/NEU.0000000000000264 (discussion 300–291)CrossRefPubMed

16.

Mathieu D, Kondziolka D, Flickinger JC et al (2007) Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 60:460–468. https://doi.org/10.1227/01.NEU.0000255340.26027.53 (discussion 468–470)CrossRefPubMed

17.

Mautner VF, Baser ME, Thakkar SD et al (2002) Vestibular schwannoma growth in patients with neurofibromatosis type 2: a longitudinal study. J Neurosurg 96:223–228. https://doi.org/10.3171/jns.2002.96.2.0223 CrossRefPubMed

18.

Mautner VF, Lindenau M, Baser ME et al (1996) The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 38:880–885 (discussion 885–886)CrossRefPubMed

19.

Nowak A, Dziedzic T, Czernicki T et al (2015) Strategy for the surgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2. Neurol Neurochir Pol 49:295–301. https://doi.org/10.1016/j.pjnns.2015.06.008 PubMed

20.

Odat HA, Piccirillo E, Sequino G et al (2011) Management strategy of vestibular schwannoma in neurofibromatosis type 2. Otol Neurotol 32:1163–1170. https://doi.org/10.1097/MAO.0b013e3182267f17 CrossRefPubMed

21.

Parry DM, Eldridge R, Kaiser-Kupfer MI et al (1994) Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:450–461. https://doi.org/10.1002/ajmg.1320520411 CrossRefPubMed

22.

Peyre M, Goutagny S, Bah A et al (2013) Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. Neurosurgery 72:907–913. https://doi.org/10.1227/NEU.0b013e31828bae28 (discussion 914; quiz 914)CrossRefPubMed

23.

Roehm PC, Mallen-St Clair J, Jethanamest D et al (2011) Auditory rehabilitation of patients with neurofibromatosis type 2 by using cochlear implants. J Neurosurg 115:827–834. https://doi.org/10.3171/2011.5.JNS101929 CrossRefPubMedPubMedCentral

24.

Rouleau GA, Merel P, Lutchman M et al (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363:515–521. https://doi.org/10.1038/363515a0 CrossRefPubMed

25.

Samii M, Gerganov V, Samii A (2006) Improved preservation of hearing and facial nerve function in vestibular schwannoma surgery via the retrosigmoid approach in a series of 200 patients. J Neurosurg 105:527–535. https://doi.org/10.3171/jns.2006.105.4.527 CrossRefPubMed

26.

Samii M, Gerganov V, Samii A (2008) Microsurgery management of vestibular schwannomas in neurofibromatosis type 2: indications and results. Prog Neurol Surg 21:169–175. https://doi.org/10.1159/000156905 PubMed

27.

Samii M, Matthies C (1997) Management of 1000 vestibular schwannomas (acoustic neuromas): the facial nerve-preservation and restitution of function. Neurosurgery 40:684–694 (discussion 694–685)CrossRefPubMed

28.

Samii M, Matthies C, Tatagiba M (1997) Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 40:696–705 (discussion 705–696)CrossRefPubMed

29.

Sepehrnia A, Borghei-Razavi H (2015) Vestibular schwannoma between 1 and 3 cm: importance of the tumor size in surgical and functional outcome. Clin Neurol Neurosurg 129:21–26. https://doi.org/10.1016/j.clineuro.2014.11.020 CrossRefPubMed

30.

Slattery WH 3rd, Brackmann DE, Hitselberger W (1998) Hearing preservation in neurofibromatosis type 2. Am J Otol 19:638–643PubMed

31.

Slattery WH 3rd, Fisher LM, Hitselberger W et al (2007) Hearing preservation surgery for neurofibromatosis type 2-related vestibular schwannoma in pediatric patients. J Neurosurg 106:255–260. https://doi.org/10.3171/ped.2007.106.4.255 CrossRefPubMed

32.

Sughrue ME, Yang I, Aranda D et al (2010) Hearing preservation rates after microsurgical resection of vestibular schwannoma. J Clin Neurosci 17:1126–1129. https://doi.org/10.1016/j.jocn.2010.01.018 CrossRefPubMed

33.

Sun S, Liu A (2014) Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis type 2. J Neurosurg 121(Suppl):143–149. https://doi.org/10.3171/2014.8.GKS141503 PubMed

34.

Tysome JR, Macfarlane R, Durie-Gair J et al (2012) Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2. Otol Neurotol 33:466–472. https://doi.org/10.1097/MAO.0b013e318248eaaa CrossRefPubMed

35.

Wanibuchi M, Fukushima T, Friedman AH et al (2014) Hearing preservation surgery for vestibular schwannomas via the retrosigmoid transmeatal approach: surgical tips. Neurosurg Rev 37:431–444. https://doi.org/10.1007/s10143-014-0543-9 (discussion 444)CrossRefPubMed

36.

Wanibuchi M, Fukushima T, McElveen JT Jr et al (2009) Hearing preservation in surgery for large vestibular schwannomas. J Neurosurg 111:845–854. https://doi.org/10.3171/2008.12.JNS08620 CrossRefPubMed

Title: Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation
Authors: Fu Zhao
Bo Wang
Zhijun Yang
Qiangyi Zhou
Peng Li
Xingchao Wang
Jing Zhang
Junting Zhang
Pinan Liu
Publication date: 01-06-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2812-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Clinical routine assessment of palliative care symptoms and concerns and caregiver burden in glioblastoma patients: an explorative field study

The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity

CyberKnife robotic radiosurgery in the multimodal management of acromegaly patients with invasive macroadenoma: a single center’s experience

Long-term hearing outcomes after gamma knife surgery in patients with vestibular schwannoma with hearing preservation: evaluation in 92 patients with serial audiograms

Incidence and survival of gliomatosis cerebri: a population-based cancer registration study

Salvage therapy outcomes for atypical meningioma